<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904225</url>
  </required_header>
  <id_info>
    <org_study_id>NPC 2018 Tegio</org_study_id>
    <nct_id>NCT03904225</nct_id>
  </id_info>
  <brief_title>Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis</brief_title>
  <official_title>Efficacy and Safety Evaluation of Tegio Consolidation Therapy in the Treatment of Nasopharyngeal Carcinoma With High Risk of Metastasis: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      oral administration of Tegio capsules for 12 months for NPC patients with high risk of
      metastasis (AJCC stage T3-4N2M0 or T1-4N3M0) was tested trying to reduce distant
      metastasis，safety was also evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, NPC patients (stage T3-4N2M0 or T1-4N3M0) who finished the curative
      chemoradiation will be randomized to the observation group and treatment group (60 mg bid,
      p.o.，d1-28，q6wks; continued until disease progression, unacceptable toxicity, or over 1
      year). The primary endpoint is distant failure-free survival (D-FFS), Secondary end points
      include overall survival (OS), locoregional failure-free survival (LR-FFS), progression-free
      survival (PFS) and toxic effects,. All efficacy analyses are conducted in the
      intention-to-treat population, and the safety population include only patients who receive
      their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant metastsis-free survival (DMFS)</measure>
    <time_frame>From date of randomization until the date of first documented distant disease failure, assessed up to 36 months</time_frame>
    <description>distant metastsis-free survival</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>tegio</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegio 60mg bid d1-28 q6wks was administered until disease progression, unacceptable toxicity,or over 12monthes within 3monthes after curative chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients was oberved</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegafur-Gimeracil-Oteracil</intervention_name>
    <description>oral administration for 12 months</description>
    <arm_group_label>tegio</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 ys

          2. Performance status of Eastern Cooperative Oncology Group (ECOG) grade 0 -2

          3. Tumor staged as 8th American Joint Committee on Cance (AJCC) T3-4N2M0 or T1-4N3M0 with
             histologically confirmed

          4. Within 12weeks after completion of the curative radiotherapy treatment

          5. disease was controlled after radiotherapy

          6. with adequate hematologic (neutrophil count &gt; 1.5×10^9/L, hemoglobin &gt; 90g/L and
             platelet count &gt; 100×10^9/L), hepatic (alanine aminotransferase, aspartate
             aminotransferase ≤ 1.5×ULN, bilirubin ≤ 1.5×ULN, alkaline phosphatase &lt; 2.5×ULN) and
             renal function (creatinine clearance &gt; 50 ml/min)

          7. Patients must be informed and written informed consent was finished.

        Exclusion Criteria:

          1. allergic to Tegio.

          2. Illness may interfere with oral medication, including dysphagia, chronic diarrhea, or
             ileus

          3. Prior malignancy except treated basal cell or in situ cervical cancer.

          4. Pregnancy or lactation (consider pregnancy test in women of child-bearing age and
             emphasize effective contraception during the treatment period).

          5. severe comorbidities may bring unacceptable risk or affect the compliance of the
             trial, including but not limited to unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose &gt;
             1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>feng Jiang, MD</last_name>
    <phone>0086-571-88128202</phone>
    <email>jiangfeng@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaozhong Chen, MD</last_name>
      <phone>86-571-88122098</phone>
      <email>cxzfyun@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xiaozhong Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 3, 2019</last_update_submitted>
  <last_update_submitted_qc>April 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>Tegio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

